Advertisement
Canada markets close in 43 minutes

  • S&P/TSX

    21,980.18
    +94.80 (+0.43%)
     

  • S&P 500

    5,109.59
    +61.17 (+1.21%)
     

  • DOW

    38,284.76
    +198.96 (+0.52%)
     

  • CAD/USD

    0.7321
    -0.0002 (-0.03%)
     

  • CRUDE OIL

    83.75
    +0.18 (+0.22%)
     

  • Bitcoin CAD

    87,369.37
    -900.60 (-1.02%)
     

  • CMC Crypto 200

    1,333.90
    -62.64 (-4.49%)
     

  • GOLD FUTURES

    2,350.40
    +7.90 (+0.34%)
     

  • RUSSELL 2000

    2,003.65
    +22.53 (+1.14%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,948.73
    +336.97 (+2.16%)
     

  • VOLATILITY

    14.96
    -0.41 (-2.67%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6837
    +0.0016 (+0.23%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Latest stubborn U.S. inflation reading will bring about more 'wait and see' from the Fed

Today’s Research Reports on Stocks to Watch: Sage Therapeutics and GW Pharmaceuticals

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / November 22, 2017 / Sage Therapeutics shares soared on Tuesday despite any news, but it seems traders were acting favorably to the company announcing the closing of its underwritten public offering last week. The company also released positive results earlier in the month on brexanolone which has the potential to treat postpartum depression. Shares of GW Pharmaceuticals also headed higher yesterday after releasing positive data on its marijuana drug Epidiolex.

RDI Initiates Coverage on:

Sage Therapeutics, Inc.
http://www.rdinvesting.com/report/?ticker=SAGE

GW Pharmaceuticals plc
http://www.rdinvesting.com/report/?ticker=GWPH

ADVERTISEMENT

Sage Therapeutics, Inc. shares closed up 7.21% at $89.94 on Tuesday with a little over 736,000 shares traded. It was last week that the clinical-stage biopharma company announced the closing of its previously announced underwritten public offering of common stock. The public offering includes the exercise in full by the underwriters of their option to purchase an additional 529,411 shares at the public offering price of $85 a share. It was earlier in the month that the stock also popped 40% when it announced positive results in trials for a drug that could potentially one day treat postpartum depression. The results from two Phase 3 trials found that the drug, called brexanolone, saw a significant reduction in depression symptoms after only 60 hours. This is a much faster treatment than options currently available. According to Canaccord Genuity, the actuality of an FDA approval increased to around 80% after the trials. The firm also upped their price target for the company to $140. The company's CEO Jeff Jonas remarked on CNBC, "We are on the cusp of a major discovery."

Access RDI's Sage Therapeutics, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=SAGE

GW Pharmaceuticals plc shares closed up 11.13% yesterday on nearly 1.5 million shares traded after the company released updated clinical trial data on its marijuana drug. Epidiolex, a cannabidiol, showed efficacy as a monotherapy and improvement from baseline over long-term use. The medicine is being evaluated for use in patients that have two rare forms of epilepsy called Lennox-Gastaut syndrome and Dravet syndrome. The company has also filed for Food and Drug Administration approval for the medicine. According to the results, 35% of Lennox-Gastaut syndrome patients responded to Epidiolex monotherapy, but only 13% of patients responded to a placebo. In the Dravet syndrome patients, there was a 57% to 59% reduction in total monthly seizures at week 60 while in Lennox-Gastaut syndrome patients, there was a 62% to 70% drop in seizures from baseline at week 60. CEO Justin Gover remarked, "Having recently completed our New Drug Application submission to the FDA, we are now focused on the goal of gaining approval for Epidiolex in mid-2018 and making this much-needed, first-in-class medicine available to the patients who need it."

Access RDI's GW Pharmaceuticals plc Research Report at:
http://www.rdinvesting.com/report/?ticker=GWPH

Our Actionable Research on Sage Therapeutics, Inc. (NASDAQ: SAGE) and GW Pharmaceuticals plc (NASDAQ: GWPH) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com